Daily Ards Research Analysis
Across three impactful ARDS studies, a meta-analysis of RCTs found no survival advantage of driving pressure–limited ventilation over conventional lung-protective strategies, though ICU stay was shorter. A prospective EIT study identified pre-prone dorsal shunt percentage as an early predictor of prone responsiveness. A VV ECMO meta-analysis showed substantially higher mortality in immunocompromised patients, especially those with hematologic malignancies, underscoring careful selection.
Summary
Across three impactful ARDS studies, a meta-analysis of RCTs found no survival advantage of driving pressure–limited ventilation over conventional lung-protective strategies, though ICU stay was shorter. A prospective EIT study identified pre-prone dorsal shunt percentage as an early predictor of prone responsiveness. A VV ECMO meta-analysis showed substantially higher mortality in immunocompromised patients, especially those with hematologic malignancies, underscoring careful selection.
Research Themes
- Ventilator strategy optimization in ARDS (driving pressure vs conventional lung-protective ventilation)
- Physiologic phenotyping and early prediction of prone response using EIT
- Outcomes of VV ECMO in immunocompromised acute respiratory failure
Selected Articles
1. Driving pressure-limited ventilation strategies versus conventional lung protective ventilation strategies for patients with ARDS/ARF: a systematic review and meta-analysis of randomized controlled trials.
This RCT-only meta-analysis found no short-term survival advantage of driving pressure–limited ventilation over conventional lung-protective ventilation in ARDS/ARF, though ICU length of stay was shorter. Findings support continued use of conventional strategies while awaiting larger trials to define DP-limiting’s role and phenotypes that may benefit.
Impact: It directly addresses a widely discussed surrogate (driving pressure) with RCT evidence synthesis, clarifying that targeting DP has not yet translated into survival benefit.
Clinical Implications: Maintain conventional lung-protective ventilation (low tidal volume, appropriate PEEP) rather than adopting DP-limited protocols as standard; consider DP as a monitoring/optimization target but not as a standalone treatment strategy pending further evidence.
Key Findings
- Meta-analysis of 4 RCTs found no short-term mortality benefit of DP-limited ventilation versus conventional lung-protective ventilation in ARDS/ARF.
- ICU length of stay was shorter with DP-limited strategies despite no survival advantage.
- Study was pre-registered (PROSPERO CRD420251069853), supporting methodological transparency.
Methodological Strengths
- RCT-only inclusion with systematic multi-database search
- Prospective protocol registration (PROSPERO) and focus on hard outcomes (mortality)
Limitations
- Only four RCTs with potentially limited power and heterogeneity of implementation protocols
- Incomplete reporting of some secondary outcomes and DP-standardization procedures across trials
Future Directions: Large, pragmatic RCTs to test DP-targeted protocols with standardized measurement, phenotype-enrichment strategies, and patient-centered outcomes.
BACKGROUND: Although driving pressure (DP) has been consistently demonstrated to be an independent predictor of mortality in mechanically ventilated patients, the clinical benefits of DP-limited ventilation strategies compared with conventional lung protective ventilation (CLPV) for patients with acute respiratory distress syndrome/acute respiratory failure (ARDS/ARF) remain controversial. METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) that compared DP-limited ventilation strategies with CLPV in patients with ARDS/ARF. The Cochrane Central Register of Controlled Trials, EMBASE, PubMed, Web of Science and Scopus databases were systematically searched from inception to June 2025. The primary outcome was short-term mortality. RESULTS: A total of 1417 records were identified, with 4 studies ( CONCLUSIONS: Based on current limited evidence, DP-limited ventilation showed no clear benefit over CLPV in patients with ARDS/ARF, with no survival benefit and a shorter length of ICU stay, warranting large RCTs to determine its clinical value, identify responsive clinical phenotypes, and establish standardized clinical application procedures. TRIAL REGISTRATION: The research plan was registered at PROSPERO, and the registration number is CRD420251069853. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-025-05722-y.
2. Predicting early prone position ventilation responsiveness in patients with acute respiratory distress syndrome based on electrical impedance tomography: a prospective study.
In 94 adults with moderate-to-severe ARDS, 83% responded to prone positioning. Pre-prone EIT-derived dorsal shunt percentage (ROI 3) and higher respiratory system compliance differentiated responders, enabling early prediction of PPV benefit.
Impact: Provides a bedside, physiology-based predictor of prone responsiveness using EIT, supporting precision ventilation and reducing unnecessary PPV exposure.
Clinical Implications: Use baseline EIT to estimate dorsal shunt percentage before proning; patients with higher pre-prone dorsal shunt and better compliance are more likely to benefit from PPV, aiding selection and timing.
Key Findings
- Among 94 ARDS patients, 78 (83%) were PPV responders and 16 (17%) were nonresponders.
- Higher pre-prone dorsal (ROI 3) shunt percentage measured by EIT predicted PPV responsiveness.
- Responders exhibited higher respiratory system compliance than nonresponders.
Methodological Strengths
- Prospective design with standardized EIT measurements
- Objective physiological endpoints linking imaging-derived shunt to response
Limitations
- Single-center study limiting generalizability
- Incomplete reporting of some numerical thresholds and potential confounders
Future Directions: Validate EIT-based shunt metrics and thresholds in multicenter cohorts and test EIT-guided proning strategies in randomized trials.
BACKGROUND: Studies have demonstrated that over 20% of patients with moderate to severe acute respiratory distress syndrome (ARDS) do not exhibit significant improvement in oxygenation following prone positioning ventilation (PPV). It is vital to investigate the modifiable characteristics associated with PPV, which would facilitate targeted interventions and minimize the adverse effects of PPV. This study aimed to investigate the physiological effects of PPV by using electrical impedance tomography (EIT), and to explore the predictors of response to PPV in patients with moderate to severe ARDS during the early phase. METHODS: This is a single-center, prospective, observational study. Ninety-four adult patients who were diagnosed with moderate-to-severe ARDS according to the Berlin definition (PaO RESULTS: Of the 94 enrolled patients, 78 (83%) were PPV responders and 16 (17%) were nonresponders. Compared to the nonresponders, the respiratory system compliance (Crs) in responders was significantly higher (35.6 ± 7.5 cmH CONCLUSION: For moderate to severe ARDS patients, the shunt% in ROI 3 before PPV could help to predict the response of PPV during the early phase.
3. Prognosis of Immunocompromised Patients With Respiratory Failure Managed With Venovenous Extracorporeal Membrane Oxygenation.
Across 13 studies, immunocompromised adults receiving VV ECMO for respiratory failure had a pooled mortality of 63% and over twofold higher odds of death than immunocompetent counterparts. Excess mortality was particularly pronounced in patients with hematologic malignancies.
Impact: Synthesizes heterogeneous real-world evidence to inform VV ECMO candidacy and risk stratification in immunocompromised patients, a growing and high-risk ARDS population.
Clinical Implications: Consider differential prognosis when evaluating immunocompromised patients for VV ECMO, with particular caution in hematologic malignancy; reinforce goals-of-care discussions and individualized selection.
Key Findings
- Pooled mortality for immunocompromised patients on VV ECMO was 63% (95% CI: 49–76%; I2: 94.23%).
- Immunocompromised status was associated with higher mortality versus immunocompetent patients (OR 2.57; 95% CI: 1.22–5.41; p=0.03; I2: 48.18%).
- Among subgroups, only hematologic malignancy showed significantly higher mortality (OR 5.78; 95% CI: 1.07–31.29; p=0.05; I2: 0%).
Methodological Strengths
- Systematic multi-database search and quantitative synthesis
- Subgroup analysis by type of immunosuppression
Limitations
- High heterogeneity (I2 94%) across included studies and observational designs
- Potential confounding and selection bias; limited adjustment for disease severity
Future Directions: Prospective registries and harmonized reporting for VV ECMO in immunocompromised patients, with severity-adjusted analyses and disease-specific risk models.
Despite the increasing number of critically ill immunocompromised patients in intensive care unit, the outcome of different types of immunocompromised patients with respiratory failure managed with venovenous extracorporeal membrane oxygenation (VV ECMO) remains unclear. What is the overall mortality of immunocompromised patients with respiratory failure managed on VV ECMO compared to immunocompetent patients? Are there differences between different types of immunocompromised states? This is a systematic review and meta-analysis using MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials for studies of any design that reported outcomes of immunocompromised adult patients managed on VV ECMO for respiratory failure. A total of 13 studies were included. The pooled mortality among immunocompromised patients undergoing VV ECMO was 63% (95% confidence interval [CI]: 49-76%, I2: 94.23%), which was significantly higher than immunocompetent patients (odds ratio [OR]: 2.57, 95% CI: 1.22-5.41, p = 0.03, I2: 48.18%). Among immunocompromised subgroups, only patients with hematologic malignancy exhibited significantly higher mortality (OR: 5.78, 95% CI: 1.07-31.29, p = 0.05, I2: 0.00%). Immunocompromised patients with acute respiratory failure treated with VV ECMO were associated with higher mortality compared to immunocompetent patients. Mortality varied by underlying cause of immunosuppression, emphasizing the need for careful, individualized patient selection.